VKORC1 and CYP2C9 genotypes and phenprocoumon anticoagulation status: Interaction between both genotypes affects dose requirement

Clinical Pharmacology and Therapeutics

Volumn 81, Issue 2, 2007, Pages 185-193

  Schalekamp, T ^a   Brasse B P ^b   Roijers, J F M ^b   Van Meegen, E ^c   Van Der Meer, F J M ^d   Van Wijk, E M ^b   Egberts, A C G ^a,b   De Boer, A ^a  

^a UTRECHT UNIVERSITY   (Netherlands)

^b CPRLab   (Netherlands)

^c Red Cross Hospital Den Haag   (Netherlands)

^d LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 2C9; PHENPROCOUMON; PROTEIN SUBUNIT; UNCLASSIFIED DRUG; VITAMIN K EPOXIDE REDUCTASE COMPLEX 1 SUBUNIT;

ADULT; AGED; ANTICOAGULATION; ARTICLE; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DRUG DOSE REDUCTION; DRUG SENSITIVITY; FEMALE; FOLLOW UP; GENE FREQUENCY; GENETIC POLYMORPHISM; GENOTYPE; HEART ATRIUM FIBRILLATION; HETEROZYGOTE; HUMAN; LINEAR REGRESSION ANALYSIS; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; STATISTICAL MODEL;

AGED; ALLELES; ANTICOAGULANTS; ARYL HYDROCARBON HYDROXYLASES; CHI-SQUARE DISTRIBUTION; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FOLLOW-UP STUDIES; GENE FREQUENCY; GENOTYPE; HUMANS; KAPLAN-MEIERS ESTIMATE; LINKAGE DISEQUILIBRIUM; MALE; MIDDLE AGED; MIXED FUNCTION OXYGENASES; PHENPROCOUMON; POLYMORPHISM, GENETIC; PROSPECTIVE STUDIES; TIME FACTORS; TREATMENT OUTCOME;

EID: 33846578240     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/sj.clpt.6100036     Document Type: Article

References (38)

1. Glasheen, J.J., Fugit, R.V. & Prochazka, A.V. The risk of overanticoagulation with antibiotic use in outpatients on stable warfarin regimens. J. Gen. Intern. Med. 20, 653-656 (2005).
2. Penning-van Beest, F.J.A., Meegen v, E., Rosendaal, F.R. & Stricker, B.H.C. Characteristics of anticoagulant therapy and comorbidity related to overanticoagulation. Thromb. Haemost. 86, 569-574 (2001).
3. Visser, L.E., Penning-van Beest, F.J.A., Kasbergen, H.A.A., De Smet, P.A.G.M., Vulto, A.G. & Hofman, A. et al. Overanticoagulation associated with combined use of antibacterial drugs and acenocoumarol or phenprocoumon anticoagulants. Thromb. Haemost. 88, 705-710 (2002).
4. Hirsh, J., Dalen, J.E., Anderson, D.R., Poller, L., Bussey, H. & Ansell, J. et al. Oral anticoagulants: Mechanism of action, clinical effectiveness and optimal therapeutic range. Chest 119, 8S-21S (2001).
5. Ansell, J., Hirsh, J., Poller, L., Bussey, H., Jacobson, A. & Hylek, E. The pharmacology and management of the vitamin K antagonists: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126(3 Suppl): 204S-233S (2004).
6. Kirchheiner, J. & Brockmoller, J. Clinical consequences of cytochrome P450 2C9 polymorphisms. Clin. Pharmacol. Ther. 77, 1-16 (2005).
7. Daly, A.K. & King, B.P. Pharmacogenetics of oral anticoagulants. Pharmacogenetics 13, 247-252 (2003).
8. Rojas, J.C., Aguilar, B., Rodriguez-Maldonado, E. & Collados, M.T. Pharmacogenetics of oral anticoagulants. Blood. Coagul. Fibrin. 16, 389-398 (2005).
9. Ufer, M. Comparative pharmacokinetics of vitamin K antagonists: warfarin, phenprocoumon and acenocoumarol. Clin. Pharmacokinet 44, 1227-1246 (2005).
10. Sanderson, S., Emery, J. & Higgins, J. CYP2C9 gene variants, drug dose, and bleeding risk in warfarin-treated patients: a HuGEnet systematic review and meta-analysis. Genet. Med. 7, 97-104 (2005).
11. Li, T., Chang, C.Y., Jin, D.Y., Lin, P.J., Khvorova, A. & Stafford, D.W. Identification of the gene for vitamin K epoxide reductase. Nature 427, 541-544 (2004).
12. Rost, S., Fregin, A., Ivaskevicius, V., Conzelmann, E., Hortnagel, K. & Pelz, H.J. et al. Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2. Nature 427, 537-541 (2004).
13. Veenstra, D.L., You, J.H., Rieder, M.J., Farin, F.M., Wilkerson, H.W. & Blough, D.K. et al. Association of Vitamin K epoxide reductase complex 1 (VKORC1) variants with warfarin dose in a Hong Kong Chinese patient population. Pharmacogenet. Genom. 15, 687-691 (2005).
14. Wadelius, M., Chen, L.Y., Downes, K., Ghori, J., Hunt, S. & Eriksson, N. et al. Common VKORC1 and GGCX polymorphisms associated with warfarin dose. Pharmacogenomics J. 5, 262-270 (2005).
15. D'Andrea, G., D'Ambrosio, R.L., DiPerna, P., Chetta, M., Santacroce, R. & Brancaccio, V. et al. A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin. Blood 105, 645-649 (2005).
16. Sconce, E.A., Khan, T.I., Wynne, H.A., Avery, P., Monkhouse, L. & King, B.P. et al. The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen. Blood 106, 2329-2333 (2005).
17. Rieder, M.J., Reiner, A.P., Gage, B.F., Nickerson, D.A., Eby, C.S. & McLeod, H.L. et al. Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N. Engl. J. Med. 352, 2285-2293 (2005).
18. Aquilante, C.L., Langaae, T.Y., Lopez, L.M., Yarandi, H.N., Tromberg, J.S. & Mohuczy, D. et al. Influence of coagulation factor, vitamin K epoxide reductase complex subunit 1, and cytochrome P450 2C9 gene polymorphisms on warfarin dose requirements. Clin. Pharmacol. Ther. 79, 291-302 (2006).
19. Mushiroda, T., Ohnishi, Y., Saito, S., Takahashi, A., Kikuchi, Y. & Shimomura, H. et al. Association of VKORC1 and CYP2C9 polymorphisms with warfarin dose requirements in Japanese patients. J. Hum. Genet. 51, 249-253 (2006).
20. Li, T., Lange, L., Li, X., Susswein, L., Bryant, B. & Malone, R. et al. Polymorphisms in the VKORC1 gene are strongly associated with warfarin dosage requirements in patients receiving anticoagulation. J. Med. Genet. 43, 740-744 (2006).
21. Schalekamp, T., Brassé, B.P., Roijers, J.F., Chahid, Y., van Geest-Daalderop, J.H. & de Vries-Goldschmeding, H. et al. VKORC1 and CYP2C9 genotypes and acenocoumarol anticoagulation status: Interaction between both genotypes affects over anticoagulation. Clin. Pharmacol. Ther. 80, 13-22 (2006).
22. Bodin, L., Verstuyft, C., Tregouet, D.A., Robert, A., Dubert, L. & Funck-Brentano, C. et al. Cytochrome P450 2C9 (CYP2C9) and vitamin K epoxide reductase (VKORC1) genotypes as determinants of acenocoumarol sensitivity. Blood 106, 135-140 (2005).
23. Reitsma, P.H., van der Heijden, J.F., Groot, A.P., Rosendaal, F.R. & Buller, H.R. A C1173T dimorphism in the VKORC1 gene determines coumarin sensitivity and bleeding risk. PLoS Med. 2, e312 (2005).
24. Schalekamp, T., Oosterhof, M., van Meegen, E., van der Meer, F.J.M., Conemans, J. & Hermans, M. et al. Effect of cytochrome P450 2C9 polymorphisms on phenprocoumon anticoagulation status. Clin. Pharmacol. Ther. 76, 409-417 (2004).
25. Visser, L.E., van Vliet, M., van Schaik, R.H.H., Kasbergen, H.A.A., De Smet, P.A.G.M. & Vulto, A.G. et al. The risk of overanticoagulation in patients with cytochrome P450 CYP2C9*2 or CYP2C9*3 alleles on acenocoumarol or phenprocoumon. Pharmacogenetics 14, 1-7 (2004).
26. Ufer, M. Effects of CYP2C9 polymorphisms on phenprocoumon anticoagulation status. Clin. Pharmacol. Ther. 77, 335-336 (2005) author reply 336.
27. Ufer, M., Kammerer, B., Kahlich, R., Kirchheiner, J., Yasar, U. & Brockmoller, J. et al. Genetic polymorphisms of cytochrome P450 2C9 causing reduced phenprocoumon (S)-7-hydroxylation in vitro and in vivo. Xenobiotica 34, 847-859 (2004).
28. Ufer, M., Svensson, J.O., Krausz, K.W., Gelboin, H.V., Rane, A. & Tybring, G. Identification of cytochromes P450 2C9 and 3A4 as the major catalysts of phenprocoumon hydroxylation in vitro. Eur. J. Clin. Pharmacol. 60, 173-182 (2004).
29. Kirchheiner, J., Ufer, M., Walter, E.-C., Kammerer, B., Kahlich, R. & Meisel, C. et al. Effects of CYP2C9 polymorphisms on the pharmacokinetics of R- and S-phenprocoumon in healthy volunteers. Pharmacogenetics 14, 19-26 (2004).
30. Geisen, C., Watzka, M., Sittinger, K., Steffens, M., Daugela, L. & Seifried, E. et al. VKORC1 haplotypes and their impact on the inter-individual and inter-ethnical variability of oral anticoagulation. Thromb. Haemost. 94, 773-779 (2005).
31. Jahnchen, E., Meinertz, I., Gilfrich, H.J., Groth, U. & Martini, A. The enantiomers of phenprocoumon: pharmacodynamic and pharmacokinetic studies. Clin. Pharmacol. Ther. 20, 342-349 (1976).
32. Hummers-Pradier, E., Hess, S., Adham, I.M., Papke, T., Pieske, B. & Kochen, M.M. Determination of bleeding risk using genetic markers in patients taking phenprocoumon. Eur. J. Clin. Pharmacol. 59, 213-219 (2003).
33. Anonymous. Standaard Afhandeling Cumarine Interacties, www.fnt.nl (2003).
34. Harder, S. & Thurmann, P. Clinically important drug interactions with anticoagulants. An update. Clin. Pharmacokinet. 30, 416-444 (1996).
35. Hylek, E.M., Chang, Y., Skates, S.J., Hughes, R.A. & Singer, D.E. Prospective study of the outcomes of ambulatory patients with excessive warfarin anticoagulation. Arch. Intern. Med. 160, 1612-1617 (2000).
36. Meer van der, F.J.M., Rosendaal, F.R., Vandenbroucke, J.P. & Briët, E. Assessment of a bleeding risk index in two cohorts of patients treated with oral anticoagulants. Thromb. Haemost. 76, 12 (1996).
37. Visser, L.E., Bleumink, G.S., Trienekens, P.H., Vulto, A.G., Hofman, A. & Stricker, B.H. The risk of overanticoagulation in patients with heart failure on coumarin anticoagulants. Br. J. Haematol. 127, 85-89 (2004).
38. Visser, L.E., van Schaik, R.H., van Vliet, M., Trienekens, P.H., De Smet, P.A. & Vulto, A.G. et al. Allelic variants of cytochrome P450 2C9 modify the interaction between nonsteroidal anti-inflammatory drugs and coumarin anticoagulants. Clin. Pharmacol. Ther. 77, 479-485 (2005).